BASILEA N news, videos and press releases
For more news please use our advanced search feature.
BASILEA N - More news...
BASILEA N - More news...
- Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
- Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
- Basilea provides portfolio update and outlook
- Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
- Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
- European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
- Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
- Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
- Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
- Basilea shareholders approve all proposals of the board of directors at the annual general meeting
- Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
- Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
- Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
- Basilea announces acquisition of preclinical antibiotics program from Spexis
- Basilea announces accelerated loan repayment
- Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
- Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
- Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
- Basilea reports strong revenue and profit growth in first half-year 2023
- Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea
- Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole
- Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan
- Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer
- Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update
- Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea
- Basilea announces repayment of 2022 convertible bonds
- Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan
- Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
- Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
- Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
